Postpartum Depression Drug Market Size Estimation, Top Key Players and Future Trends | Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd.
Postpartum depression (PPD), also known as postnatal depression, is a type of mood disorder that results post pregnancy. Signs of depression include, insomnia, fatigue and sadness, loss of appetite, mood swings, anxiety, and anger. Hormonal changes such as elevated prolactin levels, depleted oxytocin and thyroid hormone levels can be a cause of PPD in females.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2258
Postpartum Depression Drug Market– Drivers
Increasing research activities for treatment of PPD is expected to propel growth of the postpartum depression drug market during the forecast period. For instance, Sage Therapeutics is undergoing phase 3 clinical study for the drug —Brexanolone, which might be useful in the treatment of PPD. The study started in May 2018 and is estimated to be completed in September 2020.
Furthermore, Marinus Pharmaceuticals, is undergoing clinical phase 2 study for the drug Ganaxolone in the treatment of PPD and other mood associated disorders. The clinical study started in June 2017 and is expected to be completed in June 2019.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2258
Postpartum Depression Drug Market– Restraint
Antidepressant drugs refusals by the U.S. Food and Drug Administration (U.S FDA) are expected to be a major restraint in growth of the postpartum depression drug market over the forecast period. For instance, in April 2018, the U.S FDA refused New Drug Application of Alkermes plc.’s drug candidate ALKS 5461 which is to be administered orally. The drug could be useful in treating depressive disorders, which cannot be treated by other standard drug therapies. This refusal was due to failures in action of this oral medication.
Postpartum Depression Drug Market– Regional Analysis
On the basis of region, the global postpartum depression drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is estimated to hold dominant position in the global postpartum depression drug market during the forecast period, owing to increasing awareness of PPD. For instance, annually, May 2017 is celebrated as a National Maternal Depression Awareness Month recognizing the seriousness of depression during and after pregnancy in the U.S.
Furthermore, Asia Pacific is expected to witness significant growth in the global postpartum depression drug market during the forecast period, owing to increasing prevalence of PDD in the region. For instance, According to World Health Organization (WHO) July 2018 report, 22% of mothers in India suffer from PPD, annually.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2258
Key players operating in the global postpartum depression drug market include, Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd.
Postpartum Depression Drug Market– Taxonomy
By Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- Tricyclic Antidepressants
- Atypical Antidepressants
- Monoamine Oxidase Inhibitors (MAOIs)
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Have a Look at Related Research Insights:
About Us:Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.
Editor Details
-
Company:
- CDN Newswire
